Pemphigus vulgaris is a kind of auto-immune mucocutaneous blistering disease, and glucocorticoids are the most classic and common treatment for it. Research on the therapies for pemphigus vulgaris is abundant; however, most studies have focused on the classification of treatments and have failed to evaluate the initial dosage. Moreover, reports on tapering dosages and maintenance therapy are rarer. At present, foreign guidelines on methods for treating pemphigus vulgaris with systemic glucocorticoid therapy have come from dermatological experts from Japan, Europe, and Britain. We have no guideline of our own, and clinicians strongly rely on their experience alone. This paper expounds on safely and effectively using oral glucocorticoids in the treatment of pemphigus vulgaris from the perspectives of dosage and the course of treatment. This paper also attempts to present treating standards via related essays and guidelines and provides management strategies for treating pemphigus vulgaris with glucocorticoids.
